Showing results (351-360 of 434) with videos related to

Sort By:
Pageof 44
Endocrine-Related Cancer|May 27, 2025
Peptide receptor radionuclide therapy in malignant insulinomaDavid A Pattison, Grace Kong, Timothy Akhurst, et al.
International Journal of Radiation Biology|February 24, 2016
Strand breakage by decay of DNA-bound 124I provides a basis for combined PET imaging and Auger endoradiotherapyPavel Lobachevsky, George R Clark, Patrycja D Pytel, et al.
Journal of Neuroendocrinology|October 25, 2021
ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumoursClarisse Dromain, Marie-Pierre Vullierme, Rodney J Hicks, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2018
Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell CarcinomaKaiji Fan, Cathrin Ritter, Paul Nghiem, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 7, 2018
Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment OutcomesJohn Violet, Price Jackson, Justin Ferdinandus, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 19, 2018
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLCDavid R Spigel, Jamie E Chaft, Scott Gettinger, et al.
Journal of Alzheimer'S Disease : JAD|July 23, 2016
A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer's DiseaseCharles B Malpas, Lucy Vivash, Sila Genc, et al.
The Journal of Pathology|December 30, 2014
The genomic landscape of phaeochromocytomaAidan Flynn, Diana Benn, Roderick Clifton-Bligh, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 28, 2020
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatmentAmir Iravani, Medhat M Osman, Alison M Weppler, et al.
Pageof 44